Find a Pharmacy
Vertice Login
Info banner
A significant part of the Healthesystems vision is to create a more integrated experience for our customers

Category: Med Alert

65 posts found

Label Mix-Up Leads to Atenolol and Clopidogrel Recall

Golden State Medical Supply, Incorporated initiated a voluntary recall of Clopidogrel 75mg Tablets (lot# GS046745) and Atenolol 25mg Tablets (lot #GS046745) due to a label mix-up. Atenolol is indicated for the treatment of hypertension, to lower blood pressure, while Clopidogrel...
Read More

Quinapril and Hydrochlorothiazide Tablets Recalled Due to Impurity

Aurobindo Pharma USA, Inc. has initiated a voluntary recall of two lots of Quinapril and Hydrochlorothiazide Tablets USP 20mg / 12.5mg – fixed combination tablets indicated to lower blood pressure and treat hypertension – due to presence of Nitrosamine Drug...
Read More

Laxative Recalled Due to Microbial Contamination Dangerous to Immunocompromised

Vi-Jon, LLC has issued a nationwide voluntary recall for all lots of magnesium citrate saline laxative oral solution lemon flavor, 10 FL Oz (296 mL) due to microbial testing that identified the presence of gluconacetobacter liquefaciens. This microbe can be...
Read More

Novavax COVID-19 Vaccine Receives EUA

The FDA granted Emergency Use Authorization (EUA) to the Novavax COVID-19, Adjuvanted vaccine for individuals aged 18 and older. This vaccine is administered in two primary doses given three weeks apart. The vaccine was assessed in an ongoing randomized, blinded,...
Read More

FDA Panel Votes in Favor of Novavax COVID-19 Vaccine – Final Decision Pending

The FDA’s Vaccines and Related Biological Products Advisory Committee voted 21-0 in favor of recommending an Emergency Use Authorization (EUA) for the Novavax COVID-19 vaccine for individuals aged 18 and older. Phase 3 clinical trials with 30,000 people saw an...
Read More

Morphine Sulfate ER Recall Due to Deadly Label Mix-Up

Bryant Ranch Prepack Inc. is voluntarily recalling one lot of morphine sulfate 30 mg Extended-Release tablets and one lot of morphine sulfate 60 mg Extended-Release tablets, as the labels for these two products were mixed-up. Morphine sulfate is an opioid...
Read More

FDA Warns Consumers Not to Buy or Use Artri and Ortiga Products

The FDA is warning consumers not to purchase or use products marketed with variations of the names “Artri” or “Ortiga” due to potentially dangerous hidden active drug ingredients not listed on the product label. These products are marketed as treatments...
Read More

FDA Limits Authorized Use of Johnson & Johnson/Janssen COVID-19 Vaccine

The FDA has limited the authorized use of the Johnson & Johnson/Janssen COVID-19 Vaccine to individuals for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals who elect to receive the Johnson &...
Read More

Sandoz Recalls Orphenadrine Citrate Due to Nitrosamine Impurity

Sandoz Inc. issued a recall of 13 lots of Orphenadrine Citrate 100 mg Extended Release (ER) tablets to the consumer level due to the presence of a nitrosamine impurity. Orphenadrine is used as an adjunct to rest, physical therapy, and...
Read More

FDA Authorizes Second COVID-19 Booster Dose for Certain Populations

The FDA authorized a second booster dose of either the Pfizer or Moderna COVID-19 vaccines for individuals aged 50 and older at least four months after their first booster dose, and for immunocompromised individuals at least four months after their...
Read More

CDC Proposes Changing Opioid Guidelines

The CDC announced proposed draft updates to the Clinical Practice Guideline for Prescribing Opioids. This draft notice is available to the public and can be commented on until April 11, 2022. The CDC’s opioid guidelines have shaped opioid prescribing policies...
Read More

FDA Authorizes New Antibody Bebtelovimab for Mild-to-Moderate COVID-19

The FDA issued an emergency use authorization (EUA) for bebtelovimab, a monoclonal antibody, for the treatment of mild-to-moderate COVID-19 that retains activity against the omicron variant in patients weighing at least 88 pounds who are at high risk of progression...
Read More

FDA Issues EUA for Antiviral Evusheld as COVID-19 Prophylaxis

The FDA issued an emergency use authorization (EUA) for Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis of COVID-19. This product is only authorized for individuals not currently infected with COVID-19 who were recently exposed to...
Read More

FDA Issues EUA for Antiviral Paxlovid to Treat COVID-19

The FDA issued an emergency use authorization (EUA) for Paxlovid (nirmatrelvir tablets and ritonavir tablets co-packaged for oral use) for the treatment of mild-to-moderate COVID-19 in patients who are high risk for progression to severe COVID-19, including hospitalization or death....
Read More

FDA Authorizes Molnupiravir for Treatment of COVID-19

The FDA issued an emergency use authorization for molnupiravir for the treatment of mild-to-moderate COVID-19 who are at high risk of progression to severe COVID-19, including hospitalization and death, and for whom alternative COVID-19 treatments are not accessible or clinically...
Read More
1 2 3 4 5
lockmap-markermagnifiercrossmenuarrow-rightcross-circle